Company profile

Incorporated in
Fiscal year end
IRS number


25 Jul 19
23 Oct 19
31 Dec 19


Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue 6.27B 5.92B 5.97B 5.69B
Net income 1.43B 1.71B 1.16B 1.9B
Diluted EPS 0.87 1.04 0.71 1.16
Net profit margin 22.83% 28.89% 19.42% 33.40%
Net change in cash 21.07B 424M 1.5B 409M
Cash on hand 28.4B 7.34B 6.91B 5.41B
Cost of revenue 1.99B 1.84B 1.65B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 22.56B 20.78B 19.43B 16.56B
Net income 4.92B 1.01B 4.46B 1.57B
Diluted EPS 3.01 0.61 2.65 0.93
Net profit margin 21.81% 4.85% 22.94% 9.45%
Net change in cash 1.49B 1.18B 1.85B -3.19B
Cash on hand 6.91B 5.42B 4.24B 2.39B
Cost of revenue 6.55B 6.09B 4.97B 3.91B

Financial data from company earnings reports

Financial report summary

Management Discussion
  • U.S. revenues increased due to higher demand for Eliquis and Opdivo. Average U.S. net selling prices were 1% higher after discounts, charge-backs and rebates and are expected to be roughly flat on a full year basis.
  • Europe revenues increased due to higher demand for Opdivo and Eliquis, partially offset by foreign exchange, lower demand for established brands and lower average net selling prices.
  • Rest of the World revenues increased due to higher demand for Opdivo, Eliquis and Yervoy, partially offset by foreign exchange.
Content analysis ?
H.S. freshman Avg
New words: adalimumab, agonist, AMPLE, Anagni, armed, blinded, burden, called, caption, Catalent, cellular, central, certiorari, conducted, conversion, cutoff, Dana, decree, display, divest, earliest, esophageal, exploring, Farber, featured, free, FTC, GBM, HCC, Hematology, implementing, indirect, interfere, interval, Italy, judge, longest, mechanistic, metatstatic, molecular, numerically, oncolytic, Otezla, paediatric, petition, poster, predict, QoL, radiation, rank, redeemable, requisite, retail, rheumatoid, Rheumatology, Sequential, seropositive, solid, sorafenib, STING, symptom, temozolomide, tendered, trustee, unpaid, unwound, validly, violate, wholly, window
Removed: accessing, assumed, Biotek, cautionary, Commission, disgorgement, duty, event, expansion, important, lifted, molecule, obtain, obtaining, redeployed, release, shareholder, SK, small, strictly, transformation, unchanged